<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108846</url>
  </required_header>
  <id_info>
    <org_study_id>S-CitAD</org_study_id>
    <secondary_id>R01AG052510</secondary_id>
    <nct_id>NCT03108846</nct_id>
  </id_info>
  <brief_title>Escitalopram for Agitation in Alzheimer's Disease</brief_title>
  <acronym>S-CitAD</acronym>
  <official_title>Escitalopram for Agitation in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHSPH Center for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>JHSPH Center for Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of escitalopram for
      agitation in Alzheimer's dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to examine the efficacy and safety of escitalopram as treatment for
      agitation in Alzheimer's dementia (AD) patients. Participants with clinically significant
      agitation, and their caregiver(s), will receive a structured psychosocial intervention.
      Participants not showing a response three weeks later will be randomized 1:1 to escitalopram
      (up to 15 mg/day) or a matching placebo. Participants will receive study drug for 12 weeks,
      with in-person visits at weeks 3, 6, 9, and 12, and with telephone contacts between in-person
      visits. Following the 12-week study treatment period, participants will be followed for
      another 12 weeks without receiving study drug. Participants who do show a response to the
      psychosocial intervention will not be randomized to study drug but will be followed for the
      24-week follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Over-encapsulation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>modified- Alzheimer's Disease Cooperative Study--Clinical Global Impression of Change (mADCS-CGIC)</measure>
    <time_frame>after 12 weeks</time_frame>
    <description>Clinical Global Impression of Change</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">392</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1-3 capsules each containing placebo only once per day in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>5-15 mg/day (target: 15mg/day if tolerated)</description>
    <arm_group_label>Escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Masked placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>non-applicable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Alzheimer's dementia diagnosed clinically by the National Institute on Aging (NIA) and
             the Alzheimer's Association (AA) (2011 NIA/AA criteria)

          2. Mini-Mental State Examination (MMSE) score of 5-28 inclusive

          3. Meets the International Psychogeriatric Association (IPA) provisional criteria for
             agitation in cognitive disorders

          4. Clinically significant agitation/aggression as assessed by the Neuropsychiatric
             Inventory (NPI) for which either:

               -  The frequency is 'Very frequently,' or

               -  The frequency is 'Frequently' AND the severity is 'Moderate' or 'Marked'

          5. Provision of informed consent for participation in the study by both caregiver and
             participant (or, if participant is unable to provide informed consent, with surrogate
             consent and participant assent)

          6. Availability of a caregiver who spends at least several hours per week with the
             participant, supervises his/her care, is willing to accompany the participant to study
             visits, and is willing to participate in the study

          7. Stable (for ≥ 7 days) dosing of antipsychotics for agitation or psychosis, if being
             used at all

          8. A medication for agitation is appropriate, in the opinion of the study physician

        Exclusion criteria

          1. Has major depression, as indicated by major depressive episode (MDE) in the past 90
             days (meeting the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
             (DSM-V) criteria)

          2. Presence of another brain disease that fully explains the dementia, (e.g., extensive
             brain vascular disease, Parkinson's disease, dementia with Lewy bodies, traumatic
             brain injury, or multiple sclerosis)

          3. Residence in a skilled nursing or Long-Term Acute Care (LTAC) facility

          4. Contraindication to treatment with escitalopram as determined by a study physician,
             such as recent (30 days) use of monoamine oxidase inhibitors (MAOIs) or potential
             participant is hypersensitive to escitalopram or citalopram or any inactive
             ingredients

          5. Prior failed treatment attempt with citalopram or escitalopram for agitation after
             adequate trial, at minimally accepted dose

          6. Indication for psychiatric hospitalization or acute suicidality, in the opinion of the
             study physician

          7. Recent (&lt; 7 days) changes in antipsychotics (including brexpiprazole), or psychosis
             (delusions or hallucinations) requiring a new or change in antipsychotic treatment (in
             the opinion of the study physician)

          8. Abnormal corrected QT interval using Bazett's formula (QTcB) as determined on
             enrollment ECG (defined as &gt; 450 ms for men and &gt; 470 ms for women)

          9. Recent (30 days) presence of severely reduced renal function (as identified by a
             Glomerular filtration rate (GFR) clearance &lt; 30 mL/min) or reduced hepatic function

         10. Current treatment (within 7 days) with any of the following:

               -  anticonvulsants (other than Dilantin for seizures)

               -  antidepressants (other than trazodone, ≤ 50 mg per day at bedtime)

               -  benzodiazepines (other than lorazepam), or

               -  psychostimulants

         11. Recent (&lt; 14 days) changes in Dextromethorphan/quinidine, prazosin, and pimavanserin

         12. Recent (&lt; 14 days) use of medical marijuana

         13. Current participation in a clinical trial or in any study that may add a significant
             burden or affect neuropsychological or other study outcomes

         14. Significant communicative impairments that would affect participation in a clinical
             trial

         15. Any condition that, in the opinion of the study physician, makes it medically
             inappropriate or risky for the potential participant to enroll in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>109 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constantine Lyketsos, MD, MHS</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dave Shade, JD</last_name>
    <phone>4109558175</phone>
    <email>dshade@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Ehrhardt, MD</last_name>
    <phone>4109558175</phone>
    <email>sehrhar6@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Biomedical Research Foundation</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prasad Padala</last_name>
      <phone>501-257-2537</phone>
      <email>ppadala@uams.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chris Parkes</last_name>
      <phone>(501) 257-2504</phone>
      <email>christopher.parkes@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Prasad Padala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irvine Clinical Research</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tara Parnitvithikul</last_name>
      <phone>949-753-1663</phone>
      <email>tara@irvineclinical.com</email>
    </contact>
    <investigator>
      <last_name>Elly Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles/VA Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Bayard</last_name>
      <phone>310-478-3711</phone>
      <phone_ext>44572</phone_ext>
      <email>Katherine.Bayard@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Alex Alas</last_name>
      <phone>(310)-478-3711</phone>
      <email>Alexander.Alas@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>David Sultzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California Keck School of Medicine Memory and Aging Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauricio Becerra, MD</last_name>
      <phone>323-442-7594</phone>
      <email>mjbecerr@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Lon S. Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Pawluczy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Jewish Health Systems</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Gomez</last_name>
      <phone>305-751-8626</phone>
      <phone_ext>64101</phone_ext>
      <email>agomez@miamijewishhealth.org</email>
    </contact>
    <investigator>
      <last_name>Marc Agronin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melody Fairchild</last_name>
      <phone>312-503-7071</phone>
      <email>m-fairchild@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marko Mihailovic</last_name>
      <phone>(312) 503-9096</phone>
      <email>marko.mihailovic@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Schrift, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland VA Health Care System</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Schwartz</last_name>
      <phone>410-605-7358</phone>
      <email>Joseph.Schwartz@va.gov</email>
    </contact>
    <contact_backup>
      <email>John.Kasckow2@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>John Kasckow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheppard Pratt Health System</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marylu Ortiz</last_name>
      <phone>410-938-3135</phone>
      <email>mortiz@sheppardpratt.org</email>
    </contact>
    <investigator>
      <last_name>Scott Tyler Aaronson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine, Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nimra Jamil</last_name>
      <phone>410-550-9022</phone>
      <email>njamil2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Insights</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>20161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norhan Ibrahim</last_name>
      <phone>410-768-2629</phone>
      <email>ibrahim@clinicalinsights.com</email>
    </contact>
    <contact_backup>
      <last_name>Lawrence Adler</last_name>
      <email>adler@clinicalinsights.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lawrence Adler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimer Disease Center</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayaprabha Mane</last_name>
      <phone>617-302-6388</phone>
      <email>drmane@thealzcenter.org</email>
    </contact>
    <investigator>
      <last_name>Anil Nair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Program for Positive Aging</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Molly Turnwald</last_name>
      <phone>734-232-0393</phone>
      <email>turnwald@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Helen Kales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Guerra</last_name>
      <phone>702-701-7893</phone>
      <email>guerram@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Alan Ritter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Simon-Pearson</last_name>
      <phone>646-774-8671</phone>
      <email>laura.simonpearson@nyspi.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Davangere P. Devanand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Salem-Spencer, RN, MSN</last_name>
      <phone>585-760-6562</phone>
      <email>Susan_Salem-Spencer@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Anton Porsteinsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Eiginger</last_name>
      <phone>614-293-9023</phone>
      <email>Brooke.Eiginger@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Scharre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimer Disease Research Center; University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Henderson</last_name>
      <phone>412-692-2703</phone>
      <email>hendersonpl@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Oscar Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates, Ltd</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Pugh</last_name>
      <phone>215-957-9250</phone>
      <email>cherylpugh.ana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Weisman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Healthcare</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur Williams</last_name>
      <phone>843-724-2053</phone>
      <email>Arthur.Williams@RoperSaintFrancis.com</email>
    </contact>
    <investigator>
      <last_name>Jacobo Mintzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor AT&amp;T Memory Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Burris</last_name>
      <phone>214-818-2736</phone>
      <email>Sarah.Burris@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Cindy Marshall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Gills</last_name>
      <phone>425-453-0404</phone>
      <email>lgills@nwcrc.net</email>
    </contact>
    <investigator>
      <last_name>Shirin Schilling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary and Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramnik Sekhon</last_name>
      <phone>(403) 210-7737</phone>
      <email>ramnik.sekhon@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Zahinoor Ismail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lawson Health Research Institute/Parkwood Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Schaefer</last_name>
      <phone>(519) 455-5110</phone>
      <email>Betsy.Schaefer@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Amer Burhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuropsychopharmacology Research Group, Sunnybrook</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abby Li</last_name>
      <phone>(416) 480-6100</phone>
      <phone_ext>3185</phone_ext>
      <email>Abby.Li@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Nathan Herrmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyle Lago, MD</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>32911</phone_ext>
      <email>kyle.lago@camh.ca</email>
    </contact>
    <investigator>
      <last_name>Bruce Pollock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Memory and Aging</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayrose Cornejo</last_name>
      <email>mcornejo@memorycentre.ca</email>
    </contact>
    <investigator>
      <last_name>Giovanni Marotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>January 16, 2019</last_update_submitted>
  <last_update_submitted_qc>January 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>JHSPH Center for Clinical Trials</investigator_affiliation>
    <investigator_full_name>Dave Shade</investigator_full_name>
    <investigator_title>Director, S-CitAD Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Agitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

